Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

Publication | Open Access

DOI Full Paper Access

203

Citations

References

2023

Year

Eric Van Cutsem, Maria Di Bartolomeo, Elizabeth Smyth, Ian Chau, Haeseong Park, Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer A. Ajani, Joseph Chao,

The Lancet Oncology

Disease ProgressionGastrointestinal OncologyMedicineGastroenterologyPathologyHer2-positive Advanced GastricCancer TreatmentPhase 2OncologyRadiation OncologyCancer Research